U.S. market Closed. Opens in 1 hour 58 minutes

NLSPW | NLS Pharmaceutics AG Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
RevenueN/AN/AN/AN/AN/AN/A
Cost of Revenue11.41K11.41K10.05KN/AN/AN/A
Gross Profit-11.41K-11.41K-10.05KN/AN/AN/A
Operating Expenses11.81M15.47M11.85M2.30M4.20M3.45M
Selling, General & Admin5.90M6.49M5.93M2.20M2.49M2.01M
Research & Development5.91M8.98M5.92M99.58K1.70M1.44M
Other Operating Expenses010.04K-17.32K-328.37KN/A-629.23K
Operating Income-11.81M-15.48M-11.86M-2.30M-4.20M-3.45M
Other Expenses / Income-364.97K-1.01M-85.46K-562.07K-1.25M-629.23K
Before Tax Income-12.17M-16.50M-11.95M-2.86M-5.45M-5.15M
Income Tax Expenses2.002.00-226.51K-2.30K-4.20K1.70M
Net Income-12.17M-16.50M-11.95M-2.86M-5.45M-5.15M
Interest Expenses145.15K100.87K68.13K233.70K819.71K1.07M
Basic Shares Outstanding38.18M19.68M14.75M4.82M11.14M11.78M
Diluted Shares Outstanding38.18M19.68M14.75M4.82M11.14M11.78M
EBITDA-11.80M-15.47M-11.85M-2.30M-4.20M-3.45M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-12.03M-16.39M-12.10M-2.63M-4.63M-2.38M
EBIT Margin0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙